<code id='867BB3DBAA'></code><style id='867BB3DBAA'></style>
    • <acronym id='867BB3DBAA'></acronym>
      <center id='867BB3DBAA'><center id='867BB3DBAA'><tfoot id='867BB3DBAA'></tfoot></center><abbr id='867BB3DBAA'><dir id='867BB3DBAA'><tfoot id='867BB3DBAA'></tfoot><noframes id='867BB3DBAA'>

    • <optgroup id='867BB3DBAA'><strike id='867BB3DBAA'><sup id='867BB3DBAA'></sup></strike><code id='867BB3DBAA'></code></optgroup>
        1. <b id='867BB3DBAA'><label id='867BB3DBAA'><select id='867BB3DBAA'><dt id='867BB3DBAA'><span id='867BB3DBAA'></span></dt></select></label></b><u id='867BB3DBAA'></u>
          <i id='867BB3DBAA'><strike id='867BB3DBAA'><tt id='867BB3DBAA'><pre id='867BB3DBAA'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:knowledge    Page View:531
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In